# Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment

> **NCT02389231** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital, Bordeaux** · enrollment: 2 (actual)

## Conditions studied

- Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** Interleukine-2

## Key facts

- **NCT ID:** NCT02389231
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-17
- **Primary completion:** 2018-11-16
- **Final completion:** 2018-11-16
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2019-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02389231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02389231, "Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02389231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*